The clinical screenings for newborns have been helpful to diagnose such hemoglobinopathies. Specific regions of the gene encoding the beta globin chain of hemoglobin (HBB gene), such as coding regions, intro-exon boundaries, proximal promoter, 5' and 3' untranslated regions, and intronic mutations IVS-II-654, IVS-II-705 and IVS-II-745 can also be sequenced (target sequencing) for accurate diagnosis. However, mutations and deletions outside these routine targets can be easily missed. Herein, we report a complex case of a 6-week-old newborn identified with a rare HBB variant, Hb Hope, concurrent with two heterozygous deletions of HBB promoter and exons 1-2, leading to simultaneous beta-thalassemia. These deletions failed to be identified initially via ordinary deletion/duplication test. Methods: CE-HPLC, IEF and multiplex ligation-dependent probe amplification of the beta globin gene cluster (HBB, HBD, HBG1, HBG2, HBE1) and its locus control region were used for laboratory diagnostic. Results: Due to co-migration and co-elution, screening for hemoglobinopathies via IFE and CE-HPLC in this patient revealed only Hb F and absence of Hb A. However, the beta globin gene full sequencing identified Hb Hope [β136(H14) Gly→Asp (GGT→GAT)], a rare HBB variant which is not clinically significant. Furthermore, beta globin gene complete sequencing also revealed two additional deletions: HBB promoter on one allele and deletion of exons 1-2 on the other allele. Therefore, the diagnosis of concurrent beta-thalassemia major was also made. Conclusion: Due to the analytical limitation of current laboratory tests, more specific laboratory evaluations are occasionally necessary to establish an accurate diagnosis in complex cases. Introduction: It has been identified that the nondiagnostic/ unsatisfactory rate (ND/UNS) of thyroid fine needle aspirations (FNAs) is dependent on the operators who provide the samples; however, little is published on whether the diagnostic interpretation of the pathologists contributes to the problem of suboptimal thyroid samples. Methods: A total of 679 thyroid FNAs sent to St. Boniface Hospital in Winnipeg, Canada, were randomly selected and reviewed retrospectively. Cases read by pathologists who had interpreted <20 cases were excluded, resulting in 628 cases randomly assigned to 12 pathologists. The final cytologic diagnoses were recorded, and the overall ND/ UNS was determined for the group as well as for each individual pathologist. Conclusions: Of the 628 cases, 145 were signed out by the pathologist as ND/UNS (23%). The average number of FNAs per pathologist was 52, with the individual numbers ranging from 22 to 103 FNAs per pathologist. The individual ND/UNS for each pathologist ranged from 14% to 34%, the deviation from the group average of 23% ranged from -9% to +11%. Six pathologist ND/ UNS rates were higher than the group average, five were lower, and one pathologist's ND/UNS rate corresponded to the group average. The ND/UNS rates demonstrated individual differences by each pathologist; however, the distribution of the individual rates was relatively symmetric about the group average. Even the lowest ND/UNS rate was higher than what most studies have published by different groups. We conclude that pathologists may yield individual differences in applying criteria for nondiagnostic/unsatisfactory FNAs. Low cellularity of the incoming samples, however, is an area needing to be addressed (perhaps best by rapid on-site assessment) to decrease overall ND/UNS rates and improve patient care.
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Impact of a Laboratory-Based Utilization Management Program on Hereditary Hemochromatosis HFE Gene Testing
Hermineh Aramin, Carley Woodruff, Shiquan He, MS, Jessica Dodge, MD; Danbury Hospital, Danbury, CT
Introduction: Hereditary hemochromatosis (HH) secondary to HFE gene mutations is characterized by the accumulation of iron in various organs. The most common mutations are C282Y and H63D. Western Connecticut Health Network actively promotes evidence-based utilization. Our goal was to use an algorithm for the diagnosis of HH in order to reduce unnecessary HFE gene tests. Methods: An algorithm was developed for appropriate HFE gene testing. Beginning on January 1, 2014, testing met algorithmic criteria if the patient had a family history of HH or transferrin saturation was >45%. If the algorithmic criteria were not met, the test was only allowed after a pathology resident or pathologist discussed the case with the ordering healthcare provider. A retrospective review of HFE gene test results between January 1, 2013, and December 31, 2016 was performed. Cost savings analysis was performed. The Pearson χ 2 test was used for statistical analysis. Conclusions: During the three-year study, 290 HFE gene tests were reviewed, and 66 (22.8%) were canceled, with a resulting cost savings of $11,523.99 ($3,841.33 per year). In 2016, 40 HFE gene tests were indicated per the algorithm, and eight (20%) showed clinically significant HFE genotypes, whereas 30 HFE gene tests were performed on patients who did not met the criteria, and none showed clinically significant HFE mutations. The most common reasons for performing the test despite not meeting algorithmic criteria were as follows: 1) elevated serum ferritin, 2) previously elevated transferrin saturation and 3) physician request. This laboratory-based utilization management program resulted in cost savings and an overall decrease in HFE gene testing with no statistically significant decrease in clinically significant HFE genotypes. None of the HFE gene tests that were performed in 2016 despite not meeting algorithmic criteria showed clinically significant genotypes. This fact provides reassurance that utilization of the algorithm diminished waste without compromising patient care.
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The The risk of transmission of hepatitis C virus (HCV) or human immunodeficiency virus (HIV)from a transfusion is approximately one in 2 million donations per disease per transfusion. One cause is false-negative (FN) test results where the assay limit of detection is higher than viral load. Sigma metrics provides a quality measure of an assay in terms of defects per million which can be translated into FN per million results. The Cobas AmpliScreen HCV test v2.0 is approved for donor screening, and the Architect HIV Ag/Ab Combo assay is approved to be used as an alternative in urgent situations where traditional tests are unavailable or their use is impractical. We assessed our Roche Cobas AmpliPrep/ Cobas TaqMan System with the HCV test v2.0 assay, and Abbott Architect i2000SR with the HIV Ag/Ab Combo assay using sigma metrics to determine our FN result rates to better assess possible causes of residual viral transmission despite nucleic acid testing. Controls were selected at 2.84 log-copies/mL and at 2.74 log-copies/mL for HCV and HIV, respectively. The coefficients of variation (CVs) were calculated by repeated measures of control materials (n = 100 for HCV; n = 37 for HIV) after log transformation. For both assays, a 0.3 log-copies/mL variability limit was chosen as the allowable total error (TEa), representing a clinically significant change in viral load. Sigma metrics were calculated using the following equation: sigma metric = TEa/%CV. The %CVs for HCV and HIV assays were 21.96% and 22.48%, and sigma metrics were 4.5 and 4.4, respectively. A sigma value of 4 to 5 corresponds to 32 defects per million in the long-term sigma scale. Our results showed a higher FN rate of these two methods than the US Food and Drug Administration's goal. We also demonstrated the value of measuring sigma metrics when evaluating commercial screening methods. Determination of sigma metrics for other blood donor screening assays (eg, hepatitis B virus) is warranted.
